215 related articles for article (PubMed ID: 26272743)
21. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
22. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E; Bagnardi V; Rotmensz N; Viale G; Pruneri G; Veronesi P; Cancello G; Balduzzi A; Dellapasqua S; Cardillo A; Luini A; Zurrida S; Gentilini O; Mastropasqua MG; Bottiglieri L; Iorfida M; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2010 Dec; 124(3):689-99. PubMed ID: 20625816
[TBL] [Abstract][Full Text] [Related]
23. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
24. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
Gonzalez-Angulo AM; McGuire SE; Buchholz TA; Tucker SL; Kuerer HM; Rouzier R; Kau SW; Huang EH; Morandi P; Ocana A; Cristofanilli M; Valero V; Buzdar AU; Hortobagyi GN
J Clin Oncol; 2005 Oct; 23(28):7098-104. PubMed ID: 16192593
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy.
Stecklein SR; Park M; Liu DD; Valle Goffin JJ; Caudle AS; Mittendorf EA; Barcenas CH; Mougalian S; Woodward WA; Valero V; Sahin AA; Yang WT; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):568-577. PubMed ID: 29928946
[TBL] [Abstract][Full Text] [Related]
26. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.
Ko ES; Han H; Han BK; Kim SM; Kim RB; Lee GW; Park YH; Nam SJ
Korean J Radiol; 2015; 16(5):986-95. PubMed ID: 26357493
[TBL] [Abstract][Full Text] [Related]
28. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
[TBL] [Abstract][Full Text] [Related]
29. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
30. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
31. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
32. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
33. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
[TBL] [Abstract][Full Text] [Related]
34. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
35. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
Sanford RA; Lei X; Barcenas CH; Mittendorf EA; Caudle AS; Valero V; Tripathy D; Giordano SH; Chavez-MacGregor M
Ann Surg Oncol; 2016 May; 23(5):1515-21. PubMed ID: 26678405
[TBL] [Abstract][Full Text] [Related]
36. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
37. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
38. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
39. From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer.
Abdel-Razeq H; Marei L; Saadeh SS; Abdulelah H; Abu-Nasser M; Salam M; Daana W; Al-Haj Ali B; Taqash A
Breast Cancer Res Treat; 2017 Oct; 165(3):771-777. PubMed ID: 28667456
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]